New Class of Anticancer Agents
By Biotechdaily staff writers
Posted on 22 Aug 2003
Two new compounds showing broad-spectrum antitumor activity are a new class of phenylarsonic acid (PAA) derivatives.Posted on 22 Aug 2003
The compounds, PHI-370 and PHI-380, are designed to be less toxic than the chemotherapy drug arsenic trioxide. They were developed by scientists at Parker Hughes Cancer Center (Roseville, MN, USA) and have been shown to kill ovarian, testicular, multiple myloma, and acute lymphoblastic leukemia cells. PHI-380 was found to be very active against primary tumor cells isolated from the biopsy specimens of 14 patients with therapy-resistant small-cell lung cancer, breast cancer, colon cancer, lymphoma, and hepatablastoma.
"Because these drugs were active against therapy-resistant cancer cells, we hope they may one day provide the basis for effective salvage regimens for patients with recurrent cancer,” said Faith Uckun, M.D., Ph.D., medical director of Parker Hughes Cancer Center. The center is part of Parker Hughes Institute, a nonprofit research organization devoted to the discovery of new treatments for cancer.
Related Links:
Parker Hughes
Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
